References
1. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020; 369 : m1849. doi: 10.1136/bmj.m1849.
2. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020;382 (19): 1787-1799. doi: 10.1056/NEJMoa2001282.
3. Arshad U, Pertinez H, Box H, et al. Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.Clin Pharmacol Ther 2020. doi: 10.1002/cpt.1909.
4. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395 (10236): 1569-1578. doi: 10.1016/S0140-6736(20)31022-9.
5. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. N Engl J Med 2020. DOI: 10.1056/NEJMoa2007764
6. Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. MedRxiv. 2020. doi: https://doi.org/10.1101/2020.03.17.20037432
7. Ledford H, Coronavirus breakthrough: dexamethasone is first drug shown to save lives Nature 2020 doi: 10.1038/d41586-020-01824-5
8. Bakshi RP, Tatham LM, Savage AC, et al. Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. Nat Commun2018; 9 (1): 315. doi: 10.1038/s41467-017-02603-z.
9. Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV 2017; 4 (8): e331-e340. doi: 10.1016/S2352-3018(17)30068-1.